Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases

Endokrynologia Polska

Volumn 57, Issue 4, 2006, Pages 452-455

  Mucha, Sławomir A ^a   Kunert Radek, Jolanta ^a   Pomorski, Lech ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Medullary thyroid carcinoma; Metastases; Positron emission tomography

Indexed keywords

CALCITONIN; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; MEDULLARY CARCINOMA; METASTASIS; METHODOLOGY; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; THYROID TUMOR; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; CALCITONIN; CARCINOMA, MEDULLARY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 39049177934     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Schlumberger M, Pacini F. Medullary thyroid carcinoma. In: Thyroid tumors. (Schlumberger M, Pacini F, eds). Nucleon, Paris, 2003: 305-336.
2. Grauer A, Raue F, Gagel RF. Changing concepts in the management of hereditary and sporadic medullary thyroid carcinoma. Endocrinol Metab Clin North Am 1990; 19: 613-635.
3. Gharib H, McConahey WM, Tiegs RD et al. Medullary thyroid carcinoma: clinicopathologic features and long-term follow-up of 65 patients treated during 1946 through 1970. Mayo Clin Proc 1992; 67: 934-940.
4. Scollo C, Baudin E, Travagli JP et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2003; 88: 2070-2075.
5. Baudin E, Lumbroso J, Schlumberger M et al. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med 1996; 37: 912-916.
6. Gordon BA, Flanagan FL, Dehdashti F. Whole-body positron emission tomography: normal variations, pitfalls and technical considerations. Am J Radiol 1997; 169: 1675-1680.
7. Musholt TJ, Musholt PB, Dehdashti F et al. Evaluation of flu-orodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: a clinical and molecular study. Surgery 1997; 122: 1049-1061.
8. Szakall Jr S, Esik O, Bajzik G et al. 18F-FDG-PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 2002; 43: 66-71.
9. De Groot JWB, Links ThP, Jager PL et al. Impact of 18F-fluoro-2-deoxy-D- glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 2004; 11: 786-794.
10. Pomorski L, Bartkowiak J, Pisarek H et al. Medullary thyroid carcinoma (MTC) - clinical and molecular aspects on the basis of own experience. Neoplasma 2000; 47: 323-326.